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Abstract
Background: Interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (SSc).
Although the pathogenesis of SSc-ILD is not well understood, neutrophils may play a pivotal role in this process.
Neutrophils store azurophil granules that contain defensins, antimicrobial peptides that function in regulating the
inflammatory response, and IL-8, a potent chemoattractant for neutrophils. The present study evaluated the levels
of defensins and IL-8 in patients with SSc-ILD to determine their roles in disease pathogenesis.
Methods: Defensins (also known as human neutrophil peptides, HNPs) and IL-8 levels were measured in the serum
and bronchoalveolar lavage fluid (BALF) of 33 patients with SSc-ILD and in 20 healthy controls by using ELISA.
Results: BALF analysis revealed a significant increase in HNPs in SSc-ILD patients (median; 240.0 pg/mL) than that
of healthy controls (79.7 pg/mL). Additionally, IL-8 levels were higher in SSc-ILD patient serum and BALF as
compared to healthy controls (16.4 pg/mL vs. 5.8 pg/mL and 15.4 pg/mL vs. 14.5 pg/mL, respectively). However,
plasma HNPs levels were relatively unchanged. HNP and IL-8 levels in patient BALF displayed a significant positive
correlation significantly correlated (r = 0.774, p <0.01), and which also correlated with clinical disease
parameters—such as ILD biomarkers, pulmonary function tests, ratio of neutrophils and eosinophils in BALF,
tricuspid regurgitation peak gradient (TRPG), and the extent of high-resolution computed tomography (HRCT)
findings in the lung. Levels of plasma HNPs and serum IL-8 did not show a significant correlation with any clinical
parameter. SSc-ILD progression was evaluated by pulmonary function tests, but no association was observed
between VC change ratios and HNPs or IL-8 levels.
Conclusions: BALF levels of HNPs and IL-8 were higher in SSc-ILD than in healthy controls, and are associated with
various clinical disease parameters. Further studies are needed to clarify the role of defensins and IL-8 in SSc-ILD
pathogenesis.
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Background
Systemic sclerosis (SSc) is a heterogeneous disease char-
acterized by small vessel vasculopathy, autoantibody pro-
duction, and fibroblast dysfunction leading to increased
extracellular matrix deposition [1]. SSc often affects
multiple systems, including the skin and visceral organs.
Pulmonary involvement is prominent in SSc, and inter-
stitial lung disease (ILD) is the leading cause of mortality
in SSc patients [2]. Although SSc-ILD pathogenesis is
not well understood, the aberrant function of a variety of
lung cells, cytokines, growth factors, peptides, and bio-
active proteins, in combination with genetic and epigen-
etic regulators, have crucial functions in this process [3].
High-resolution computed tomography (HRCT) is the
standard method for the noninvasive diagnosis of SSc-
ILD and can detect mild abnormalities [4]. The extent of
disease observed with HRCT and lower diffusing cap-
acity of carbon monoxide (DLco) are reported to be as-
sociated with poor SSc-ILD prognosis [5, 6]. Although
the cellular analysis of bronchoalveolar lavage fluid
(BALF) is limited to excluding infection [4], it has been
reported that neutrophilia in BALF is associated with
disease severity [7].
IL-8 is a potent neutrophil chemoattractant. As such,
elevated IL-8 levels in BALF often correlate with
pulmonary neutrophil accumulation and poor function
tests in SSc-ILD patients [8], as well as extensive fibro-
sis in HRCT [9]. Correspondingly, IL-8 mRNA is
shown to be upregulated in fibroblasts derived from lo-
calized scleroderma lesions in these patients [10, 11].
Thus, these data support a possible role of IL-8 in SSc-
ILD pathogenesis.
Defensins are small, arginine-rich cationic peptides
with antimicrobial activity [12]. Humans express α- and
β-defensins. Among the six known α-defensins, human
neutrophil peptides (HNP)-1 to 4 are mainly found in
neutrophils, whereas human defensins (HD)-5 and HD-6
are primarily expressed in intestinal Paneth cells, and
the respiratory and female reproductive tracts [13].
Human β defensins (HBDs) are expressed by epithelial
cells in the skin and at mucosal surfaces in contact with
the environment. Defensins play antimicrobial roles, and
might also function in regulating inflammatory re-
sponses [14]. A series of studies have found increased
HNPs and HBD levels in plasma or BALF from patients
with various inflammatory lung diseases [15, 16]. More-
over, we previously reported that elevated HNP levels
in BALF were associated with heighted neutrophil
counts and IL-8 in patients with several lung diseases
[17–21].
Here, we evaluated the concentrations of HNPs and
IL-8 in the BALF and blood of patients with SSc-ILD to
determine their roles in disease pathogenesis.
Table 1 Characteristics of patients with SSc-ILD
N = 33
Gender (Male/Female) 10/23
Age (Years) 63 (54–70)
Duration from onset (Months) 36 (10–84)
Smoking (Non/Ex/Current) 22/8/3
Auto-antibodies
Anti-topoisomerase I Ab 17 (52 %)
Anti-centromere Ab 6 (18 %)
Anti-RNA polymerase Ab 2 (6 %)
Anti-Th/To Ab 1 (3 %)
Anti-RNP Ab 1 (3 %)
Unknown 6 (18 %)
Coexisting rheumatic disease
Sjögren's syndrome 4 (12 %)
Primary biliary cirrhosis 2 (6 %)
Sarcoidosis 2 (6 %)
Rheumatoid arthritis 1 (3 %)
Systemic lupus erythematosus 1 (3 %)
Polymyositis 1 (3 %)
Table 2 Laboratory findings in patients with SSc-ILD
Variables N median IQR
Laboratory data
PaO2 (torr) 28 92.0 (76.6–95.1)
KL-6 (U/mL) 30 973 (529–1986)
SP-D (ng/mL) 33 212 (114–308)
SP-A (ng/mL) 25 83.4 (58.3–121.5)
Pulmonary function test
%VC (%) 33 92.3 (76.4–111.8)
FEV1/FEV (%) 33 78.4 (73.5–83.7)
%DLco (%) 32 56.6 (41.2–66.9)
BALF cell findings
TCC (× 105/mL) 33 2.8 (2.3–4.4)
Macrophages (%) 33 74.8 (58.3–86.8)
Lymphocytes (%) 33 10.6 (7.9–18.7)
Neutrophils (%) 33 5.1 (1.8–12.0)
Eosinophils (%) 33 1.7 (1.0–5.9)
CD4/8 (%) 33 1.3 (0.6–2.2)
HRCT findings
Ground glass opacity (%) 33 11.7 (5.9–29.2)
Reticular opacities (%) 33 6.7 (1.7–15.9)
TRPG 30 25.5 (18.0–30.5)
IQR inter-quartile range, TRPG tricuspid regurgitation peak gradient
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Methods
Study population
The study population consisted of 33 SSc-ILD patients
at Nagasaki University Hospital between 2000 and 2014
and 20 healthy volunteers. All SSc patients fulfilled the
American College of Rheumatology classification criteria
[22]. SSc-ILD was diagnosed by HRCT of the lung, and
one of these patients was pathologically diagnosed as
fibrotic nonspecific interstitial pneumonia (NSIP) by sur-
gical lung biopsy. BALF and blood samples were col-
lected at their first visit and stored at −20 °C until use.
No patient was treated by systemic steroid and/or
immunosuppressants at the sample collection. All
data, including those from pulmonary function tests,
arterial blood gas analyses, markers of interstitial
pneumonia—such as Krebs von den Lungen 6 (KL-6),
surfactant protein (SP)-A, and SP-D, and survival
rates were obtained from medical records. Screening
for pulmonary hypertension was performed by trans-
thoracic echocardiography in 30 of 33 patients, and
tricuspid regurgitation peak gradient (TRPG) was
used as indicator of pulmonary hypertension. All
healthy controls were asymptomatic, not taking any
medication, and had normal chest radiographs. All
participants provided written, informed consent before
enrollment. The study protocol was approved by the
Human Ethics Review Committee at Nagasaki Univer-
sity School of Medicine.
Evaluation of ILD
All HRCTs were obtained at the time of diagnosis
and assessed retrospectively. The extent of visual
ground glass opacity, reticular opacities, and honey-
combing were determined by visually estimating the
extent in the upper, middle, and lower zones of each
lung based on the percentage of the lung field that
showed each abnormality in each zone (estimated to
the nearest 10 % of parenchymal involvement) ac-
cording to the reports of Johkoh et al. [23] and Sumi-
kawa et al. [24]. The upper zone was defined as the
area above the level of the carina; the lower zone as
the area below the level of the inferior pulmonary
vein; and the middle zone as the area between the
upper and lower zones. Overall percentage of involve-
ment was obtained by averaging the six lung zones.
pg/mL
p < 0.01
Fig. 1 Human neutrophil peptide (HNP) levels in the BALF of SSc-ILD
patients. HNP levels were analyzed in BALF of patients with systemic
sclerosis associated interstitial lung disease (SSc-ILD) and healthy
controls by ELISA. The data is represented by Tukey boxplots
p < 0.01
pg/mL pg/mL
p < 0.01a) b)
Fig. 2 IL-8 levels in SSc-ILD patient serum and BALF. IL-8 levels were analyzed in the serum (a) and BALF (b) of SSc-ILD patients and healthy controls
by ELISA. The data is represented by Tukey boxplots
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BALF was collected with three instillations of sterile
physiological saline (50 mL) through a flexible bron-
choscope as previously described [25]. The collected
lavage fluid was passed through two sheets of gauze
and centrifuged at 400 × g for 10 min at 4 °C, and the
supernatant stored at −20 °C until use. ILD progres-
sion was evaluated by the percentage of relative de-
cline in absolute VC [26].
Measurement of HNPs and IL-8
HNP and IL-8 concentrations in serum and BALF were
measured using sandwich enzyme-linked immunosorbent
assay (ELISA) kits according to the manufacturers’ proto-
cols (HNP1-3, HyCult Biotechnology, Uden, Netherlands;
R&D Systems, Minneapolis, MN, USA). Samples were di-
luted 1000-fold for plasma HNPs, and 5-fold for serum
and BALF IL-8. The lower limit of detection was 156 pg/
Table 3 Correlation between HNPs and IL-8 and clinical parameters in patients with SSc-ILD
Variables HNPs in BALF IL-8 in BALF
N r 95 % CI P-value r 95 % CI P-value
HNPs in plasma 33 0.049 −0.299 – 0.386 0.79 −0.06 −0.395 – 0.289 0.75
HNPs in BALF 33 – – – 0.774 0.587 – 0.883 <0.01
IL-8 in serum 33 0.324 −0.022 – 0.600 0.07 0.160 −0.194 – 0.477 0.38
IL-8 in BALF 33 0.774 0.587 – 0.883 <0.01 – – –
Laboratory data
PaO2 (torr) 28 −0.416 −0.683 – −0.051 0.03 −0.429 −0.691 – −0.067 0.02
KL-6 (U/mL) 30 0.511 0.185 – 0.736 <0.01 0.467 0.128 – 0.708 <0.01
SP-D (ng/mL) 33 0.363 0.023 – 0.628 0.04 0.360 0.019 – 0.626 0.04
SP-A (ng/mL) 25 0.256 −0.155 – 0.591 0.23 0.364 −0.36 – 0.664 0.08
Pulmonary function test
%VC (%) 33 −0.575 −0.767 – −0.289 <0.01 −0.636 −0.804 – −0.374 <0.01
FEV1/FEV (%) 33 0.106 −0.246 – 0.434 0.56 −0.091 −0.421 – 0.260 0.61
%DLco (%) 32 −0.529 −0.741 – −0.221 <0.01 −0.492 −0.718 – −0.173 <0.01
BALF cell findings
TCC (× 105/mL) 33 −0.036 −0.375 – 0.311 0.84 −0.065 −0.399 – 0.285 0.72
Macrophages (%) 33 0.016 −0.329 – 0.357 0.93 −0.010 −0.352 – 0.335 0.96
Lymphocytes (%) 33 −0.153 −0.472 – 0.201 0.40 −0.167 −0.483 – 0.187 0.35
Neutrophils (%) 33 0.595 0.316 – 0.779 <0.01 0.540 0.242 – 0.745 <0.01
Eosinophils (%) 33 0.466 0.146 – 0.698 <0.01 0.419 0.088 – 0.666 0.02
CD4/8 (%) 33 −0.090 −0.420 – 0.261 0.62 −0.009 −0.351 – 0.335 0.96
HRCT findings
Ground glass opacity (%) 33 0.711 0.486 – 0.848 <0.01 0.583 0.230 – 0.772 <0.01
Reticular opacities (%) 33 0.652 0.398 – 0.813 <0.01 0.605 0.330 – 0.785 <0.01
TRPG 30 0.517 0.193 – 0.740 <0.01 0.473 0.136 – 0.712 <0.01
Decline in absolute VC (%)
One year 15 −0.275 −0.690 – 0.276 0.32 −0.059 −0.555 – 0.467 0.84
Two years 12 −0.070 −0.619 – 0.525 0.83 0.010 −0.567 – 0.581 0.97













Fig. 3 Correlation between IL-8 and HNP levels in BALF samples
from SSc-ILD patients
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mL for HNPs and 3.5 pg/mL for IL-8. Assays were per-
formed in duplicate, and inter-/intra-assay coefficients of
variation for plasma HNPs, BALF HNPs, serum IL-8, and
BALF IL-8 were 10.6/6.3, 10.7/10.6, 12.4/7.9 and 7.8/
11.9 %, respectively.
Statistical analysis
All values are expressed as the median and inter-
quartile range (IQR). Differences between and among
groups were compared using the Mann-Whitney U and
Kruskal-Wallis tests, respectively. Correlations between
parameters were determined by Spearman’s rank correl-




Patient demographic and clinical data are shown in
Table 1. The median patient age was 63, and 10 of 33
patients were men. Several patients had coexisting
rheumatic diseases. Laboratory findings in patients with
SSc-ILD are shown in Table 2.
Plasma, serum, and BALF levels of HNPs and IL-8
HNP analysis revealed significantly higher levels in the
BALF of SSc-ILD patients (median, 240.0 pg/mL; IQR,
26.4–563.1 pg/mL) than that of healthy controls (79.7 pg/
mL, 65.6–107.8 pg/mL, p <0.01, Fig. 1); however, no
differences were observed in plasma HNPs levels (65.9 ng/
mL, 27.0–79.9 ng/mL) and SSc-ILD (101.0 ng/mL, 58.35–
141.3 ng/mL, p = 0.20). Alternatively, IL-8 levels were
higher in SSc-ILD patient serum (16.4 pg/mL, 11.3–
24.6 pg/mL vs. 5.8 pg/mL, 4.4–11.7 pg/mL in healthy
controls, p <0.01; Fig. 2a) and BALF (15.4 pg/mL, 9.5–
32.8 pg/mL vs. 14.5 pg/mL, 2.7–17.1 pg/mL in healthy
controls, p <0.01; Fig. 2b).
Association between HNPs, IL-8, and clinical parameters
in SSc-ILD
We then analyzed the relationships between clinical param-


































Fig. 4 Correlation between (HNPs; a) or IL-8 (b) levels and neutrophil percentage in BALF samples from SSc-ILD patients
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SSc-ILD patients (Table 3). Notably, the levels of BALF
HNPs and BALF IL-8 correlated significantly (r = 0.774,
Fig. 3). Both BALF HNPs and IL-8 levels were posi-
tively correlated with serum KL-6 (HNPs; r = 0.511,
IL-8; r = 0.467), SP-D (r = 0.363, r = 0.360), and the
percentage of neutrophils (r = 0.595, r = 0.540; Fig. 4)
and eosinophils (r = 0.466, r = 0.419) in BALF, and nega-
tively correlated with PaO2 (r = −0.416, r = −0.429), VC
(r = −0.575, r = −0.636), and DLco (r = −0.529, r = −0.492;
Fig. 5). Moreover, both HNPs and IL-8 BALF levels were
positively correlated with TRPG (r = 0.517, r = 0.473). Levels
of plasma HNPs and serum IL-8 did not show a significant
correlation with any clinical parameters. SSc-ILD progres-
sion was evaluated by the percentage of relative decline in
absolute VC in 15 patients over 1 year and 13 of 32 patients
for 2 years, but no associations were observed.
Discussion
In the present study, we found elevated levels of BALF
HNPs, BALF IL-8, and serum IL-8 in SSc-ILD patients
when compared with healthy controls, but no significant
differences were observed with respect to plasma HNPs.
Both BALF HNPs and IL-8 levels were associated with
clinical parameters, such as markers of interstitial pneu-
monia (KL-6, SP-D), pulmonary function tests, ratios of
neutrophils and eosinophils in BALF, and the extent of
lung HRCT findings. Notably, this is the first study to
suggest that HNPs in BALF play a primary role in SSc-
ILD pathophysiology.
SSc-ILD severity is reported to be associated with BALF
IL-8 levels [8]. This was supported by our data, which also
added a correlation with BALF HNPs. Moreover, both
HNPs and IL-8 in BALF correlated with neutrophil num-
ber in the present study. It has been reported that SSc-
ILD severity associated with neutrophilia in BALF [5].
BALF HNPs and IL-8 levels also showed a positive correl-
ation. We previously reported that HNPs and IL-8 levels
in BALF showed a positive correlation in patients with
idiopathic pulmonary fibrosis (IPF) [18]. Furthermore,















Fig. 5 Correlation between (HNPs; a, c) or IL-8 (b, d) BALF levels and pulmonary function tests in SSc-ILD patients
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8—and growth factors, which play pivotal roles in pul-
monary fibrosis, in lung fibroblasts and epithelial cells, as
well as the production of collagen by lung fibroblasts in
vitro [12, 27, 28]. Altogether, these results suggest that
HNPs produced by neutrophils induce IL-8 production in
the lung and play a pivotal role in SSc-ILD.
The association between neutrophilia in BALF and dis-
ease progression in SSc-ILD is controversial. Crestani et
al. reported that spontaneous IL-8 secretion by alveolar
macrophages was higher in patients with SSc than con-
trol subjects, and positively correlated with the percent-
age of neutrophils in BALF [29]. From this, they
concluded that alveolar macrophages contribute to the
influx of neutrophils in alveoli through the release of IL-
8. Moreover, Goh et al. reported that neutrophilia in
BALF is linked to early mortality, but not to long-term
survival or the progression of lung disease [7]. Alter-
natively, De Santis et al. reported that the neutrophi-
lia in BALF is significantly associated with overall
mortality, but is not an independent risk factor of
mortality [30]. Our data did not show any association
between disease progression and HNPs, IL-8, or
neutrophils in the BALF of SSc-ILD patients. Never-
theless, our present results and others [5, 30] indicate
that not only neutrophils, but also HNPs and IL-8 in
BALF associate with SSc-ILD severity, but not disease
progression. Thus, further studies are needed to clar-
ify the association among HNPs, IL-8 and neutrophils
in SSc-ILD.
In contrast to BALF HNPs, plasma HNPs levels were
not elevated in SSc-ILD nor did they show any correla-
tions with clinical parameters. Our previous reports found
elevated plasma HNPs in patients with bacterial infection,
acute respiratory distress syndrome, IPF, diffuse pan-
bronchiolitis, and pulmonary tuberculosis [18–20, 31,
32], but not with pulmonary non-tuberculous Mycobac-
terial infections [21]. Plasma HNPs were also negatively
correlated with pulmonary function tests in patients with
IPF [18]. Although the precise mechanism of plasma HNP
production is not well understood, they are mainly derived
from neutrophil precursor cells in bone marrow in re-
sponse to stimulation by inflammatory mediators [20, 33].
Accordingly, further studies are needed to clarify the dif-
ferences of plasma HNPs levels between SSc-ILD and
other diseases.
Serum IL-8 levels are reported to be elevated and
significantly correlated with decreased DLco in SSc pa-
tients [34, 35], but did not have the prognostic value
with SSc-ILD [36]. In contrast, elevated serum IL-8
levels did not correlate with clinical parameters in SSc-
ILD in our study. IL-8 mRNA levels are reported to be
upregulated in fibroblasts derived from scleroderma
skin lesions [10, 11], suggesting that serum IL-8 may
partially mediate SSc-ILD pathology. However, further
studies are needed to clarify the role of serum IL-8
levels in disease pathogenesis.
This study has several limitations. We evaluated
follow-up data of pulmonary function tests for only 1–2
years with this retrospective study, which could result in
an insufficient analysis on the participation of these
markers in SSc-ILD progression. Moreover, since the
patients were all seen in by the respiratory department,
our study only examined IL-8 and HNPs levels in SSc-
ILD patients, but not in patients without the ILD
component. Thus, we were unable to confirm that lung
pathology is responsible for changed levels of IL-8 and
HNPs in SSc patients. The small patient cohort is other
limitation of this study; thus, a larger patient population
and prospective studies are needed for future investigations.
Conclusions
HNPs in BALF, and IL-8 in serum and BALF were
higher in patients with SSc-ILD than healthy controls.
While both HNPs and IL-8 in BALF were associated
with clinical parameters, further studies are necessary to
clarify the role of defensins in SSc-ILD pathogenesis.
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